These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

188 related items for PubMed ID: 22350110

  • 1. Vitamin D reduces musculoskeletal pain after infusion of zoledronic acid for postmenopausal osteoporosis.
    Catalano A, Morabito N, Atteritano M, Basile G, Cucinotta D, Lasco A.
    Calcif Tissue Int; 2012 Apr; 90(4):279-85. PubMed ID: 22350110
    [Abstract] [Full Text] [Related]

  • 2. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
    McClung M, Recker R, Miller P, Fiske D, Minkoff J, Kriegman A, Zhou W, Adera M, Davis J.
    Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
    [Abstract] [Full Text] [Related]

  • 3. Once-yearly administered intravenous zoledronic acid for postmenopausal osteoporosis.
    Woodis CB.
    Ann Pharmacother; 2008 Jul; 42(7):1085-9. PubMed ID: 18505912
    [Abstract] [Full Text] [Related]

  • 4. Multicenter Study on Observation of Acute-phase Responses After Infusion of Zoledronic Acid 5 mg in Chinese Women with Postmenopausal Osteoporosis.
    Ding Y, Zeng JC, Yin F, Zhang CL, Zhang Y, Li SX, Liu X, Zhang C, Xue QY, Lin H, Pei FX.
    Orthop Surg; 2017 Aug; 9(3):284-289. PubMed ID: 28960821
    [Abstract] [Full Text] [Related]

  • 5. Effect of zoledronic acid compared with raloxifene on bone turnover markers in postmenopausal women with low bone density.
    Bachmann G, Kriegman A, Gonçalves J, Kianifard F, Warren M, Simon JA.
    Menopause; 2011 Aug; 18(8):851-6. PubMed ID: 21796066
    [Abstract] [Full Text] [Related]

  • 6. Intravenous zoledronic acid in postmenopausal women with low bone mineral density.
    Reid IR, Brown JP, Burckhardt P, Horowitz Z, Richardson P, Trechsel U, Widmer A, Devogelaer JP, Kaufman JM, Jaeger P, Body JJ, Brandi ML, Broell J, Di Micco R, Genazzani AR, Felsenberg D, Happ J, Hooper MJ, Ittner J, Leb G, Mallmin H, Murray T, Ortolani S, Rubinacci A, Saaf M, Samsioe G, Verbruggen L, Meunier PJ.
    N Engl J Med; 2002 Feb 28; 346(9):653-61. PubMed ID: 11870242
    [Abstract] [Full Text] [Related]

  • 7. Characterization of and risk factors for the acute-phase response after zoledronic acid.
    Reid IR, Gamble GD, Mesenbrink P, Lakatos P, Black DM.
    J Clin Endocrinol Metab; 2010 Sep 28; 95(9):4380-7. PubMed ID: 20554708
    [Abstract] [Full Text] [Related]

  • 8. Cost-minimization study comparing annual infusion of zoledronic acid or weekly oral alendronate in women with low bone mineral density.
    Chávez-Valencia V, Arce-Salinas CA, Espinosa-Ortega F.
    J Clin Densitom; 2014 Sep 28; 17(4):484-9. PubMed ID: 24613450
    [Abstract] [Full Text] [Related]

  • 9. Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole.
    Brufsky A, Bundred N, Coleman R, Lambert-Falls R, Mena R, Hadji P, Jin L, Schenk N, Ericson S, Perez EA, Z-FAST and ZO-FAST Study Groups.
    Oncologist; 2008 May 28; 13(5):503-14. PubMed ID: 18515735
    [Abstract] [Full Text] [Related]

  • 10. Zoledronic acid: new indication. No therapeutic advantage in postmenopausal osteoporosis.
    Prescrire Int; 2008 Aug 28; 17(96):143. PubMed ID: 19480098
    [Abstract] [Full Text] [Related]

  • 11. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct 28; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 12. Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration.
    Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D.
    J Bone Miner Res; 2012 Jan 28; 27(1):227-30. PubMed ID: 21956654
    [Abstract] [Full Text] [Related]

  • 13. No effect of rosuvastatin in the zoledronate-induced acute-phase response.
    Makras P, Anastasilakis AD, Polyzos SA, Bisbinas I, Sakellariou GT, Papapoulos SE.
    Calcif Tissue Int; 2011 May 28; 88(5):402-8. PubMed ID: 21305270
    [Abstract] [Full Text] [Related]

  • 14. Cytokines and insulin resistance after zoledronic acid-induced acute phase response.
    Kassi G, Papamichael K, Papaioannou G, Giagourta I, Thanou S, Triantaphyllopoulou M, Zapanti E, Papandroulaki F, Ktena V, Karga H.
    Immunol Invest; 2014 May 28; 43(6):544-55. PubMed ID: 24661204
    [Abstract] [Full Text] [Related]

  • 15. Zoledronic acid acutely increases sclerostin serum levels in women with postmenopausal osteoporosis.
    Catalano A, Morabito N, Basile G, Brancatelli S, Cucinotta D, Lasco A.
    J Clin Endocrinol Metab; 2013 May 28; 98(5):1911-5. PubMed ID: 23596142
    [Abstract] [Full Text] [Related]

  • 16. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure.
    Recker RR, Delmas PD, Halse J, Reid IR, Boonen S, García-Hernandez PA, Supronik J, Lewiecki EM, Ochoa L, Miller P, Hu H, Mesenbrink P, Hartl F, Gasser J, Eriksen EF.
    J Bone Miner Res; 2008 Jan 28; 23(1):6-16. PubMed ID: 17892374
    [Abstract] [Full Text] [Related]

  • 17. Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.
    Bundred NJ, Campbell ID, Davidson N, DeBoer RH, Eidtmann H, Monnier A, Neven P, von Minckwitz G, Miller JC, Schenk NL, Coleman RE.
    Cancer; 2008 Mar 01; 112(5):1001-10. PubMed ID: 18205185
    [Abstract] [Full Text] [Related]

  • 18. Final 5-year results of Z-FAST trial: adjuvant zoledronic acid maintains bone mass in postmenopausal breast cancer patients receiving letrozole.
    Brufsky AM, Harker WG, Beck JT, Bosserman L, Vogel C, Seidler C, Jin L, Warsi G, Argonza-Aviles E, Hohneker J, Ericson SG, Perez EA.
    Cancer; 2012 Mar 01; 118(5):1192-201. PubMed ID: 21987386
    [Abstract] [Full Text] [Related]

  • 19. Acute phase response following intravenous zoledronate in postmenopausal women with low bone mass.
    Anastasilakis AD, Polyzos SA, Makras P, Sakellariou GT, Bisbinas I, Gkiomisi A, Delaroudis S, Gerou S, Ballaouri I, Oikonomou D, Papapoulos SE.
    Bone; 2012 May 01; 50(5):1130-4. PubMed ID: 22366634
    [Abstract] [Full Text] [Related]

  • 20. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M, Pogłód R, Maj S, Pawlikowski J, Sokołowska U, Szczepanik J.
    Acta Pol Pharm; 2002 May 01; 59(6):478-82. PubMed ID: 12669777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.